Abstract
This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.
Original language | English (US) |
---|---|
Pages (from-to) | 629-648 |
Number of pages | 20 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 26 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2012 |
Keywords
- Antifolates
- Folate receptor-mediated endocytosis
- Folate receptors
- Methotrexate
- Pemetrexed
- Pralatrexate
- Proton-coupled folate transporter (PCFT)
- Reduced folate carrier (RFC)
ASJC Scopus subject areas
- Hematology
- Oncology